Compare CMP & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMP | KALV |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2003 | 2014 |
| Metric | CMP | KALV |
|---|---|---|
| Price | $29.25 | $26.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $21.50 | ★ $32.60 |
| AVG Volume (30 Days) | 500.3K | ★ 4.4M |
| Earning Date | 05-06-2026 | 07-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | N/A | $185.42 |
| Revenue Next Year | $1.29 | $59.23 |
| P/E Ratio | $38.16 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $16.40 | $9.83 |
| 52 Week High | $30.04 | $26.85 |
| Indicator | CMP | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 75.27 |
| Support Level | $20.08 | $14.66 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.64 | 0.44 |
| MACD | 0.24 | 0.35 |
| Stochastic Oscillator | 87.25 | 98.47 |
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.